Orr 2009.

Methods	Participants were not taking any medications; no wash‐out was required 12‐Week double‐blind randomised placebo‐controlled trial
Participants	26 obese men and women aged 40 to 65 years; BP < 160/100 mmHg, TC < 300 mg/dL, TG < 450 mg/dL Exclusion criteria: elevated transaminase levels, BMI ≥ 25 kg/m2, brachial arterial BP ≤ 159/99 mmHg Placebo baseline TC: 5.87 mmol/L (227 mg/dL) Placebo baseline LDL‐C: 4.19 mmol/L (162 mg/dL) Placebo baseline HDL‐C: 1.11 mmol/L (43 mg/dL) Placebo baseline TG: 1.41 mmol/L (125 mg/dL) Atorvastatin 80 mg/d baseline TC: 5.46 mmol/L (211 mg/dL) Atorvastatin 80 mg/d baseline LDL‐C: 3.85 mmol/L (149 mg/dL) Atorvastatin 80 mg/d baseline HDL‐C: 1.14 mmol/L (44 mg/dL) Atorvastatin 80 mg/d baseline TG: 1.39 mmol/L (123 mg/dL)
Interventions	Placebo Atorvastatin 80 mg/d
Outcomes	Per cent change from baseline at 12 weeks of serum TC, LDL‐C, HDL‐C, TG There were no adverse events reported during the study
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information about sequence generation was insufficient to permit judgement of 'yes' or 'no'
Allocation concealment (selection bias)	Unclear risk	Information about allocation concealment was insufficient to permit judgement of 'yes' or 'no'
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured; WDAEs were reported
Other bias	High risk	Pfizer funded the trial